Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC and Arachidonic Acid Supplementation in Type 1 Diabetes
NCT03056014Phase 1Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acetylcysteine and arachidonic acid in type 1 diabetes mellitus (T1D) (6 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Change from baseline in level of oxidative stress with varying doses of NAC at 2 weeks and Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks. Started Nov 2018; status: terminated.
02
Drugs
acetylcysteinearachidonic acid
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03056014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056014.